INS and heart failure: Glucagon-like peptide modulators or sodium‒glucose cotransporter 2 inhibitors constitute the second line of therapy for stimulating insulin release and facilitating glucose uptake into cells [93], with both classes now recognized for their cardiovascular benefits beyond glucose lowering, including reduction in heart failure risk and adverse cardiac remodeling.